Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Adverse drug reactions (ADRs) are a relatively common cause of morbidity and mortality. Many factors can contribute to ADRs, including genetics. The degree to which genetics contributes to ADRs is not entirely clear and varies by drug, as well as the type of ADR. Pharmacogenetics and, more recently, pharmacogenomics have been applied to the field of ADRs for both predictable ADRs and hypersensitivity drug reactions. Evaluations for glucose-6-phosphate dehydrogenase and thiopurine S-methyltransferase are commonplace clinical tests to reduce hematologic problems associated with drugs, such as dapsone and azathioprine, respectively. Numerous pharmacogenetic associations have been discovered for immediate hypersensitivity reactions to β-lactams, aspirin, and nonsteroidal anti-inflammatory drugs; however, the clinical utility of testing for these genetic associations has not been established. In contrast, pharmacogenetic testing for HLA-B*1502 before carbamazepine in patients of certain Asian ethnicities and testing for HLA-B*5701 before abacavir treatment are recommended. This review will focus on pharmacogenetics and pharmacogenomics and their role in reducing ADRs, especially those caused by drug hypersensitivity reactions.

Original languageEnglish (US)
Pages (from-to)943-955
Number of pages13
JournalJournal of Allergy and Clinical Immunology
Volume138
Issue number4
DOIs
StatePublished - Oct 1 2016

Fingerprint

Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
Drug Hypersensitivity
HLA-B Antigens
thiopurine methyltransferase
Pharmaceutical Preparations
Immediate Hypersensitivity
Lactams
Dapsone
Glucosephosphate Dehydrogenase
Carbamazepine
Azathioprine
Genetic Testing
Aspirin
Anti-Inflammatory Agents
Morbidity
Mortality

Keywords

  • abacavir
  • adverse drug reactions
  • carbamazepine
  • drug allergy
  • drug hypersensitivity
  • nonsteroidal anti-inflammatory drug
  • Pharmacogenetics
  • pharmacogenomics
  • β-lactam

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Pharmacogenomics and adverse drug reactions : Primetime and not ready for primetime tests. / Khan, David A.

In: Journal of Allergy and Clinical Immunology, Vol. 138, No. 4, 01.10.2016, p. 943-955.

Research output: Contribution to journalReview article

@article{de9271598fad4ec5bf750548a6713d0c,
title = "Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests",
abstract = "Adverse drug reactions (ADRs) are a relatively common cause of morbidity and mortality. Many factors can contribute to ADRs, including genetics. The degree to which genetics contributes to ADRs is not entirely clear and varies by drug, as well as the type of ADR. Pharmacogenetics and, more recently, pharmacogenomics have been applied to the field of ADRs for both predictable ADRs and hypersensitivity drug reactions. Evaluations for glucose-6-phosphate dehydrogenase and thiopurine S-methyltransferase are commonplace clinical tests to reduce hematologic problems associated with drugs, such as dapsone and azathioprine, respectively. Numerous pharmacogenetic associations have been discovered for immediate hypersensitivity reactions to β-lactams, aspirin, and nonsteroidal anti-inflammatory drugs; however, the clinical utility of testing for these genetic associations has not been established. In contrast, pharmacogenetic testing for HLA-B*1502 before carbamazepine in patients of certain Asian ethnicities and testing for HLA-B*5701 before abacavir treatment are recommended. This review will focus on pharmacogenetics and pharmacogenomics and their role in reducing ADRs, especially those caused by drug hypersensitivity reactions.",
keywords = "abacavir, adverse drug reactions, carbamazepine, drug allergy, drug hypersensitivity, nonsteroidal anti-inflammatory drug, Pharmacogenetics, pharmacogenomics, β-lactam",
author = "Khan, {David A.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.jaci.2016.08.002",
language = "English (US)",
volume = "138",
pages = "943--955",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Pharmacogenomics and adverse drug reactions

T2 - Primetime and not ready for primetime tests

AU - Khan, David A.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Adverse drug reactions (ADRs) are a relatively common cause of morbidity and mortality. Many factors can contribute to ADRs, including genetics. The degree to which genetics contributes to ADRs is not entirely clear and varies by drug, as well as the type of ADR. Pharmacogenetics and, more recently, pharmacogenomics have been applied to the field of ADRs for both predictable ADRs and hypersensitivity drug reactions. Evaluations for glucose-6-phosphate dehydrogenase and thiopurine S-methyltransferase are commonplace clinical tests to reduce hematologic problems associated with drugs, such as dapsone and azathioprine, respectively. Numerous pharmacogenetic associations have been discovered for immediate hypersensitivity reactions to β-lactams, aspirin, and nonsteroidal anti-inflammatory drugs; however, the clinical utility of testing for these genetic associations has not been established. In contrast, pharmacogenetic testing for HLA-B*1502 before carbamazepine in patients of certain Asian ethnicities and testing for HLA-B*5701 before abacavir treatment are recommended. This review will focus on pharmacogenetics and pharmacogenomics and their role in reducing ADRs, especially those caused by drug hypersensitivity reactions.

AB - Adverse drug reactions (ADRs) are a relatively common cause of morbidity and mortality. Many factors can contribute to ADRs, including genetics. The degree to which genetics contributes to ADRs is not entirely clear and varies by drug, as well as the type of ADR. Pharmacogenetics and, more recently, pharmacogenomics have been applied to the field of ADRs for both predictable ADRs and hypersensitivity drug reactions. Evaluations for glucose-6-phosphate dehydrogenase and thiopurine S-methyltransferase are commonplace clinical tests to reduce hematologic problems associated with drugs, such as dapsone and azathioprine, respectively. Numerous pharmacogenetic associations have been discovered for immediate hypersensitivity reactions to β-lactams, aspirin, and nonsteroidal anti-inflammatory drugs; however, the clinical utility of testing for these genetic associations has not been established. In contrast, pharmacogenetic testing for HLA-B*1502 before carbamazepine in patients of certain Asian ethnicities and testing for HLA-B*5701 before abacavir treatment are recommended. This review will focus on pharmacogenetics and pharmacogenomics and their role in reducing ADRs, especially those caused by drug hypersensitivity reactions.

KW - abacavir

KW - adverse drug reactions

KW - carbamazepine

KW - drug allergy

KW - drug hypersensitivity

KW - nonsteroidal anti-inflammatory drug

KW - Pharmacogenetics

KW - pharmacogenomics

KW - β-lactam

UR - http://www.scopus.com/inward/record.url?scp=84992222132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992222132&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2016.08.002

DO - 10.1016/j.jaci.2016.08.002

M3 - Review article

C2 - 27720019

AN - SCOPUS:84992222132

VL - 138

SP - 943

EP - 955

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -